<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37508478</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>CXCR2 Is Deregulated in ALS Spinal Cord and Its Activation Triggers Apoptosis in Motor Neuron-Like Cells Overexpressing hSOD1-G93A.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1813</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12141813</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease characterized by progressive depletion of motor neurons (MNs). Recent evidence suggests a role in ALS pathology for the C-X-C motif chemokine receptor 2 (CXCR2), whose expression was found increased at both mRNA and protein level in cortical neurons of sporadic ALS patients. Previous findings also showed that the receptor inhibition is able to prevent iPSC-derived MNs degeneration in vitro and improve neuromuscular function in SOD1-G93A mice. Here, by performing transcriptional analysis and immunofluorescence studies, we detailed the increased expression and localization of CXCR2 and its main ligand CXCL8 in the human lumbar spinal cord of sporadic ALS patients. We further investigated the functional role of CXCR2/ligands axis in NSC-34 motor neuron-like cells expressing human wild-type (WT) or mutant (G93A) SOD1. A significant expression of CXCR2 was found in doxycycline-induced G93A-SOD1-expressing cells, but not in WT cells. In vitro assays showed CXCR2 activation by GRO&#x3b1; and MIP2&#x3b1;, two murine endogenous ligands and functional homologs of CXCL8, reduces cellular viability and triggers apoptosis in a dose dependent manner, while treatment with reparixin, a non-competitive allosteric CXCR2 inhibitor, effectively counteracts GRO&#x3b1; and MIP2&#x3b1; toxicity, significantly inhibiting the chemokine-induced cell death. Altogether, data further support a role of CXCR2 axis in ALS etiopathogenesis and confirm its pharmacological modulation as a candidate therapeutic strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Cognata</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation, National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Amico</LastName><ForeName>Agata Grazia</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maugeri</LastName><ForeName>Grazia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0173-4885</Identifier><AffiliationInfo><Affiliation>Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morello</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation, National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarnaccia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation, National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magr&#xec;</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3542-3770</Identifier><AffiliationInfo><Affiliation>Department of (Neuro) Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Meibergdreef 9, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agata</LastName><ForeName>Velia</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1114-8265</Identifier><AffiliationInfo><Affiliation>Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallaro</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7590-1792</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation, National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054426">Chemokine CXCL2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000707068">Cxcr2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000629781">CXCR2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054426" MajorTopicYN="N">Chemokine CXCL2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CXCL1</Keyword><Keyword MajorTopicYN="N">CXCL2</Keyword><Keyword MajorTopicYN="N">CXCL8</Keyword><Keyword MajorTopicYN="N">CXCR2</Keyword><Keyword MajorTopicYN="N">GRO&#x3b1;</Keyword><Keyword MajorTopicYN="N">IL-8</Keyword><Keyword MajorTopicYN="N">MIP2&#x3b1;</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">reparixin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37508478</ArticleId><ArticleId IdType="pmc">PMC10377984</ArticleId><ArticleId IdType="doi">10.3390/cells12141813</ArticleId><ArticleId IdType="pii">cells12141813</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis. Lancet. 2007;369:2031&#x2013;2041. doi: 10.1016/S0140-6736(07)60944-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60944-1</ArticleId><ArticleId IdType="pubmed">17574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile G., Morello G., La Cognata V., Guarnaccia M., Conforti F.L., Cavallaro S. Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases. J. Pers. Med. 2022;12:770. doi: 10.3390/jpm12050770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12050770</ArticleId><ArticleId IdType="pmc">PMC9143965</ArticleId><ArticleId IdType="pubmed">35629192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuuluvainen L., Kaivola K., M&#xf6;nk&#xe4;re S., Laaksovirta H., Jokela M., Udd B., Valori M., Pasanen P., Paetau A., Traynor B.J., et al. Oligogenic basis of sporadic ALS. Neurol. Genet. 2019;5:e335. doi: 10.1212/NXG.0000000000000335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000335</ArticleId><ArticleId IdType="pmc">PMC6481226</ArticleId><ArticleId IdType="pubmed">31086828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile G., Perrone B., Morello G., Simone I.L., Ando S., Cavallaro S., Conforti F.L. Individual Oligogenic Background in p.D91A-SOD1 Amyotrophic Lateral Sclerosis Patients. Genes. 2021;12:1843. doi: 10.3390/genes12121843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12121843</ArticleId><ArticleId IdType="pmc">PMC8701978</ArticleId><ArticleId IdType="pubmed">34946792</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S.A., Fang T., De Marchi F., Neel D., Van Weehaeghe D., Berry J.D., Paganoni S. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs. 2022;82:1367&#x2013;1388. doi: 10.1007/s40265-022-01769-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01769-1</ArticleId><ArticleId IdType="pubmed">36121612</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Parton M.J., Leigh P.N. Clinical trials in ALS: An overview. Semin. Neurol. 2001;21:167&#x2013;175. doi: 10.1055/s-2001-15262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-15262</ArticleId><ArticleId IdType="pubmed">11442325</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Morello G., Cavallaro S. Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases. Int. J. Mol. Sci. 2021;22:4820. doi: 10.3390/ijms22094820.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094820</ArticleId><ArticleId IdType="pmc">PMC8125201</ArticleId><ArticleId IdType="pubmed">34062930</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Golini E., Iemmolo R., Balletta S., Morello G., De Rosa C., Villari A., Marinelli S., Vacca V., Bonaventura G., et al. CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice. Neurobiol. Dis. 2021;160:105538. doi: 10.1016/j.nbd.2021.105538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105538</ArticleId><ArticleId IdType="pubmed">34743985</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Spampinato A.G., Conforti F.L., D&#x2019;Agata V., Cavallaro S. Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach. J. Mol. Neurosci. 2017;61:563&#x2013;580. doi: 10.1007/s12031-017-0898-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-017-0898-9</ArticleId><ArticleId IdType="pmc">PMC5359376</ArticleId><ArticleId IdType="pubmed">28236105</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E., Baas F., Iyer A., ten Asbroek A.L., Morello G., Cavallaro S. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis. 2015;74:359&#x2013;376. doi: 10.1016/j.nbd.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.002</ArticleId><ArticleId IdType="pubmed">25500340</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Guarnaccia M., Spampinato A.G., Salomone S., D&#x2019;Agata V., Conforti F.L., Aronica E., Cavallaro S. Integrative multi-omic analysis identifies new drivers and pathways in molecularly distinct subtypes of ALS. Sci. Rep. 2019;9:9968. doi: 10.1038/s41598-019-46355-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-46355-w</ArticleId><ArticleId IdType="pmc">PMC6620285</ArticleId><ArticleId IdType="pubmed">31292500</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Spampinato A.G., Cavallaro S. Molecular Taxonomy of Sporadic Amyotrophic Lateral Sclerosis Using Disease-Associated Genes. Front. Neurol. 2017;8:152. doi: 10.3389/fneur.2017.00152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00152</ArticleId><ArticleId IdType="pmc">PMC5395696</ArticleId><ArticleId IdType="pubmed">28469596</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple B.D., Kossmann T., Morganti-Kossmann M.C. Role of chemokines in CNS health and pathology: A focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 2010;30:459&#x2013;473. doi: 10.1038/jcbfm.2009.240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2009.240</ArticleId><ArticleId IdType="pmc">PMC2949152</ArticleId><ArticleId IdType="pubmed">19904283</ArticleId></ArticleIdList></Reference><Reference><Citation>Horuk R., Martin A.W., Wang Z., Schweitzer L., Gerassimides A., Guo H., Lu Z., Hesselgesser J., Perez H.D., Kim J., et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J. Immunol. 1997;158:2882&#x2013;2890. doi: 10.4049/jimmunol.158.6.2882.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.158.6.2882</ArticleId><ArticleId IdType="pubmed">9058825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen D., Stangel M. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res. Dev. Brain Res. 2001;128:77&#x2013;81. doi: 10.1016/S0165-3806(01)00128-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-3806(01)00128-6</ArticleId><ArticleId IdType="pubmed">11356265</ArticleId></ArticleIdList></Reference><Reference><Citation>Popivanova B.K., Koike K., Tonchev A.B., Ishida Y., Kondo T., Ogawa S., Mukaida N., Inoue M., Yamashima T. Accumulation of microglial cells expressing ELR motif-positive CXC chemokines and their receptor CXCR2 in monkey hippocampus after ischemia-reperfusion. Brain Res. 2003;970:195&#x2013;204. doi: 10.1016/S0006-8993(03)02343-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(03)02343-6</ArticleId><ArticleId IdType="pubmed">12706261</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad F.M., Reutershan J. CXCR2 in acute lung injury. Mediat. Inflamm. 2012;2012:740987. doi: 10.1155/2012/740987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/740987</ArticleId><ArticleId IdType="pmc">PMC3375097</ArticleId><ArticleId IdType="pubmed">22719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennini T., Giordano L., Mengozzi M., Ghezzi P., Tonelli R., Mantegazza R., Silani V., Corbo M., Lunetta C., Beghi E. Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. Eur. J. Inflamm. 2017;7:39&#x2013;44. doi: 10.1177/1721727X0900700105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1721727X0900700105</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M.C., Cawston E.E., Chen G., Brooks C., Douwes J., McLean D., Graham E.S., Dragunow M., Scotter E.L. Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis. BMC Neurol. 2022;22:216. doi: 10.1186/s12883-022-02730-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02730-1</ArticleId><ArticleId IdType="pmc">PMC9188104</ArticleId><ArticleId IdType="pubmed">35690735</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusconi M., Gerardi F., Santus W., Lizio A., Sansone V.A., Lunetta C., Zanoni I., Granucci F. Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients&#x2019; peripheral blood. Sci. Rep. 2017;7:7853. doi: 10.1038/s41598-017-08233-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08233-1</ArticleId><ArticleId IdType="pmc">PMC5552769</ArticleId><ArticleId IdType="pubmed">28798369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J., Smith A.J., Kuzmin-Nichols N., Zesiewicz T.A., Jahan I., Shytle R.D., Kim S.H., Sanberg C.D., Vu T.H., Gooch C.L., et al. Humoral factors in ALS patients during disease progression. J. Neuroinflammation. 2015;12:127. doi: 10.1186/s12974-015-0350-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Lindberg R.L., Regeniter A., Mehling M., Steck A.J., Kappos L., Czaplinski A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009;16:771&#x2013;774. doi: 10.1111/j.1468-1331.2009.02560.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Won Y.H., Lee M.Y., Choi Y.C., Ha Y., Kim H., Kim D.Y., Kim M.S., Yu J.H., Seo J.H., Kim M., et al. Elucidation of Relevant Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis. PLoS ONE. 2016;11:e0165290. doi: 10.1371/journal.pone.0165290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165290</ArticleId><ArticleId IdType="pmc">PMC5094695</ArticleId><ArticleId IdType="pubmed">27812125</ArticleId></ArticleIdList></Reference><Reference><Citation>Quek H., Cuni-Lopez C., Stewart R., Colletti T., Notaro A., Nguyen T.H., Sun Y., Guo C.C., Lupton M.K., Roberts T.L., et al. ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. J. Neuroinflammation. 2022;19:58. doi: 10.1186/s12974-022-02421-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02421-1</ArticleId><ArticleId IdType="pmc">PMC8887023</ArticleId><ArticleId IdType="pubmed">35227277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.J., Jiang B.C., Gao Y.J. Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. Cell. Mol. Life Sci. 2017;74:3275&#x2013;3291. doi: 10.1007/s00018-017-2513-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2513-1</ArticleId><ArticleId IdType="pubmed">28389721</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Gentile G., Aronica E., Cavallaro S. Splicing Players Are Differently Expressed in Sporadic Amyotrophic Lateral Sclerosis Molecular Clusters and Brain Regions. Cells. 2020;9:159. doi: 10.3390/cells9010159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010159</ArticleId><ArticleId IdType="pmc">PMC7017305</ArticleId><ArticleId IdType="pubmed">31936368</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma &#xd7; spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992;194:209&#x2013;221. doi: 10.1002/aja.1001940306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aja.1001940306</ArticleId><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Maugeri G., D&#x2019;Amico A.G., Rasa D.M., Federico C., Saccone S., Morello G., La Cognata V., Cavallaro S., D&#x2019;Agata V. Molecular mechanisms involved in the protective effect of pituitary adenylate cyclase-activating polypeptide in an in vitro model of amyotrophic lateral sclerosis. J. Cell. Physiol. 2019;234:5203&#x2013;5214. doi: 10.1002/jcp.27328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27328</ArticleId><ArticleId IdType="pubmed">30238989</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico A.G., Maugeri G., Saccone S., Federico C., Cavallaro S., Reglodi D., D&#x2019;Agata V. PACAP Modulates the Autophagy Process in an In Vitro Model of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:2943. doi: 10.3390/ijms21082943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21082943</ArticleId><ArticleId IdType="pmc">PMC7216177</ArticleId><ArticleId IdType="pubmed">32331311</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico A.G., Scuderi S., Maugeri G., Cavallaro S., Drago F., D&#x2019;Agata V. NAP reduces murine microvascular endothelial cells proliferation induced by hyperglycemia. J. Mol. Neurosci. 2014;54:405&#x2013;413. doi: 10.1007/s12031-014-0335-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-014-0335-2</ArticleId><ArticleId IdType="pubmed">24874579</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Maugeri G., D&#x2019;Amico A.G., Saccone S., Federico C., Cavallaro S., D&#x2019;Agata V. Differential expression of PARK2 splice isoforms in an in vitro model of dopaminergic-like neurons exposed to toxic insults mimicking Parkinson&#x2019;s disease. J. Cell. Biochem. 2018;119:1062&#x2013;1073. doi: 10.1002/jcb.26274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26274</ArticleId><ArticleId IdType="pubmed">28688199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura G., La Cognata V., Iemmolo R., Zimbone M., Contino A., Maccarrone G., Failla B., Barcellona M.L., Conforti F.L., D&#x2019;Agata V., et al. Ag-NPs induce apoptosis, mitochondrial damages and MT3/OSGIN2 expression changes in an in vitro model of human dental-pulp-stem-cells-derived neurons. Neurotoxicology. 2018;67:84&#x2013;93. doi: 10.1016/j.neuro.2018.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2018.04.014</ArticleId><ArticleId IdType="pubmed">29698629</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudani S., La Cognata V., Iemmolo R., Bonaventura G., Villaggio G., Saccone S., Barcellona M.L., Cavallaro S., Sinatra F. Effect of a Bone Marrow-Derived Extracellular Matrix on Cell Adhesion and Neural Induction of Dental Pulp Stem Cells. Front. Cell Dev. Biol. 2020;8:100. doi: 10.3389/fcell.2020.00100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00100</ArticleId><ArticleId IdType="pmc">PMC7068778</ArticleId><ArticleId IdType="pubmed">32211401</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone B., La Cognata V., Sprovieri T., Ungaro C., Conforti F.L., Ando S., Cavallaro S. Alternative Splicing of ALS Genes: Misregulation and Potential Therapies. Cell. Mol. Neurobiol. 2020;40:1&#x2013;14. doi: 10.1007/s10571-019-00717-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-019-00717-0</ArticleId><ArticleId IdType="pubmed">31385134</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Salomone S., D&#x2019;Agata V., Conforti F.L., Cavallaro S. From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis. Front. Neurosci. 2020;14:577755. doi: 10.3389/fnins.2020.577755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.577755</ArticleId><ArticleId IdType="pmc">PMC7661549</ArticleId><ArticleId IdType="pubmed">33192262</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F., Munitic I., Amedei A., Berry J.D., Feldman E.L., Aronica E., Nardo G., Van Weehaeghe D., Niccolai E., Prtenjaca N., et al. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci. Biobehav. Rev. 2021;127:958&#x2013;978. doi: 10.1016/j.neubiorev.2021.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="pubmed">34153344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Investig. 2017;127:3250&#x2013;3258. doi: 10.1172/JCI90607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90607</ArticleId><ArticleId IdType="pmc">PMC5669558</ArticleId><ArticleId IdType="pubmed">28737506</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley M.E., Baloh R.H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Walz A., Peveri P., Aschauer H., Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 1987;149:755&#x2013;761. doi: 10.1016/0006-291X(87)90432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(87)90432-3</ArticleId><ArticleId IdType="pubmed">3322281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonecchi R., Facchetti F., Dusi S., Luini W., Lissandrini D., Simmelink M., Locati M., Bernasconi S., Allavena P., Brandt E., et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J. Immunol. 2000;164:3862&#x2013;3869. doi: 10.4049/jimmunol.164.7.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.7.3862</ArticleId><ArticleId IdType="pubmed">10725748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson G., Mikovits J.A., Metcalfe D.D., Taub D.D. Mast Cell Migratory Response to Interleukin-8 Is Mediated through Interaction with Chemokine Receptor CXCR2/Interleukin-8RB. Blood. 1999;93:2791&#x2013;2797. doi: 10.1182/blood.V93.9.2791.409k27_2791_2797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V93.9.2791.409k27_2791_2797</ArticleId><ArticleId IdType="pubmed">10216072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippert U., Zachmann K., Henz B.M., Neumann C. Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2. Exp. Dermatol. 2004;13:520&#x2013;525. doi: 10.1111/j.0906-6705.2004.00182.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0906-6705.2004.00182.x</ArticleId><ArticleId IdType="pubmed">15265017</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirodi C.S., Devalaraja R., Nanney L.B., Arrindell S., Russell S., Trupin J., Richmond A. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen. 2000;8:371&#x2013;382. doi: 10.1111/j.1524-475X.2000.00371.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-475X.2000.00371.x</ArticleId><ArticleId IdType="pmc">PMC3140346</ArticleId><ArticleId IdType="pubmed">11115149</ArticleId></ArticleIdList></Reference><Reference><Citation>Strieter R.M., Polverini P.J., Arenberg D.A., Kunkel S.L. The role of CXC chemokines as regulators of angiogenesis. Shock. 1995;4:155&#x2013;160. doi: 10.1097/00024382-199509000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-199509000-00001</ArticleId><ArticleId IdType="pubmed">8574748</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Conforti F.L., Parenti R., D&#x2019;Agata V., Cavallaro S. Selection of Potential Pharmacological Targets in ALS Based on Whole-Genome Expression Profiling. Curr. Med. Chem. 2015;22:2004&#x2013;2021. doi: 10.2174/0929867322666150408112135.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867322666150408112135</ArticleId><ArticleId IdType="pubmed">25850769</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Spampinato A.G., Cavallaro S. Neuroinflammation and ALS: Transcriptomic Insights into Molecular Disease Mechanisms and Therapeutic Targets. Mediat. Inflamm. 2017;2017:7070469. doi: 10.1155/2017/7070469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7070469</ArticleId><ArticleId IdType="pmc">PMC5610842</ArticleId><ArticleId IdType="pubmed">29081603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Tortarolo M., Vallarola A., Freschi M., Pasetto L., Bonetto V., Bendotti C. New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. Brain Pathol. 2016;26:237&#x2013;247. doi: 10.1111/bpa.12351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12351</ArticleId><ArticleId IdType="pmc">PMC8029191</ArticleId><ArticleId IdType="pubmed">26780365</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola M., Buanne P., Biordi L., Bertini R., Ghezzi P., Mennini T. Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures. Neuroimmunomodulation. 2007;14:310&#x2013;316. doi: 10.1159/000123834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000123834</ArticleId><ArticleId IdType="pubmed">18391506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>